Medtech
-
Avantium
x close
Avantium
Avantium International BV provides innovative high-throughput R&D services and technologies to the pharmaceutical and chemical industries.
Avantium combines experimentation technologies, novel research methodologies and state-of-the-art software to accelerate R&D and increase the success rate and economics of the development efforts of its customers.
Avantium is headquartered in Amsterdam, Netherlands where also it has its laboratory. The Company has additional development sites in the UK and US. Avantium’s customers include GSK, Pfizer, Akzo Nobel Chemicals, Eastman and Shell Chemicals. -
De Novo
x close
De Novo
De Novo Pharmaceuticals Ltd is a computationally-based drug discovery company focused on small molecule therapeutics.
The core platform at De Novo is a suite of structure generating programs called SkelGen, which has been comprehensively evaluated and co-developed by Roche. The core algorithm generates new molecular structures by the random assembly of small molecular fragments in situ. Ninety-percent of the structures produced by SkelGen are novel and chemically tractable which represents a significant advancement in the field of De Novo design and potential paradigm shift for drug discovery.
The company was spun out of Cambridge University and maintains its headquarters in Cambridge, UK. -
DRI
x close
DRI
DNA Research Innovations (DRI) was established to develop its Charge Switch Technology (CST) to purify DNA and RNA from any source. This is the most innovative way to purify nucleic acid that has been developed for 30 years. CST enables researchers to purify DNA without using any environmentally unfriendly chemicals and without any complicated centrifugation steps. It also enables very simple automation of DNA purification which is critical to enable researchers to work more efficiently and therefore make them more productive. This will drive the understanding of genetics and disease and enable the more widespread use of DNA in forensic applications. DRI was sold to Invitrogen, the world’s biggest research reagents provider in 2004 for $65m in cash. DRI’s technology is now globally available to life science researchers. Esprit received £6m as its consideration, a return of 3x on its total investment.
-
Kiadis Pharma
x close
Kiadis Pharma
Kiadis has now merged with Celmed Biosciences to create Kiadis Pharma, a drug discovery and development company with a focus on cancer and metabolic disorders.
Kiadis Pharma has extensive experience in oncology and currently has an impressive small molecule pipeline with four products in various phases of clinical development allowing fast track potential and significant market opportunities. Its lead product, ATIR, is in Phase I/II trials and has successfully allowed blood cancer patients, without access to a fully matched donor, to receive a life-saving transplantation of bone-marrow.
Kiadis was a spin-off from the University of Leiden and Kiadis Pharma headquarters is located in Groningen.
-
Oxford BioMedica
x close
Oxford BioMedica
Oxford BioMedica is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University to exploit the intellectual property that had been developed by Professor Sue and Alan Kingsman in the use of viruses to deliver gene therapy.
Esprit invested a total of £2.2 million in Oxford Biomedica during 1998 and 2001 and realised £5.0 million through the sale of its shareholding between 2003 and 2005. Oxford BioMedica’s lead product is currently undergoing evaluation in Phase II clinical trials.Visit the Oxford BioMedica website at www.oxfordbiomedica.co.uk
-
Oxford Immunotec
x close
Oxford Immunotec
Oxford Immunotec is a world leading diagnostic company spun out from Oxford University to commercialise T SPOT™, a proprietary platform technology to simply and accurately examine a patient’s cellular immune response to infection. The first product to come from this platform is called T SPOT-TB and is designed to replace the oldest technique currently in use for the diagnosis of tuberculosis. The current test is hampered by high false positive and false negative rates and extremely poor performance in populations at risk from developing TB such as HIV+ individuals, transplant patients and cancer patients. T SPOT-TB does not suffer from any of these disadvantages and is the only commercially available product in the world that can be used effectively for all populations where testing for latent TB is important. Oxford Immunotec is currently selling T-SPOT-TB in Europe and aims to have its test FDA approved in 2007. It is headquartered in Oxford, UK.
Visit the Oxford Immunotec website at www.oxfordimmunotec.com
-
Sciona
x close
Sciona
Sciona provides personalised health and nutrition recommendations based on an individual's diet, lifestyle and unique genetic profile. It is aimed at promoting health, well-being and performance, thereby potentially reducing the risk of health problems.
Sciona's Cellf™ Genetic Assessment is a DNA, diet and lifestyle assessment test that helps the user understand their risks associated with heart health, bone health, antioxidant and detoxification, inflammation and insulin resistance. Assessments focus only on gene variations the influence of which may be offset by eating certain foods, increasing intake of specific micronutrients or making lifestyle changes. Sciona is headquartered in Boulder, CO. USA.